Topical issues of vaccination and epidemiological surveillance over measles and rubella in Ukraine.
DOI:
https://doi.org/10.26641/2307-0404.2018.1(part1).127206Ключевые слова:
vaccination, measles, rubella, eliminationАннотация
The analysis of measles and rubella morbidity, the state of their vaccination in Ukraine was carried out. Despite decades of preventive vaccination, there is a 5-6 years’ cyclicity of measles epidemic process at present time. Measles morbidity increased 46.8 times in 2017 in comparison with 2016. Elevated rates of rubella epidemic morbidity were registered in 2004 and 2011. There was decrease of routine measles and rubella immunization coverage in the period from 2009 to 2016. Critically low rates were noted in 2016 – 45.5% (vaccination) and 30.2% (revaccination). In spite of progress in the measles and rubella vaccination in 2017 (93.3% – vaccination and 90.7% – revaccination), Ukraine has not achieved the immunization coverage (≥95.0%) necessary to interrupt these pathogens circulation. The national laboratory and a network of regional ones, in-system of the Global Measles and Rubella Laboratory Network, were established in Ukraine to ensure high-quality performance of epidemiological surveillance. Genotyping of the clinical samples from Ukrainian measles and rubella patients is carried out in the WHO Regional Reference Laboratory (Luxembourg). Different genetic lines of the measles virus with prevalence of D8 genotype were indicated to circulate in Ukraine. The genotype B3 was also identified and the genotype D9 was isolated for the first time. In the furtherance of the goal of rubella and measles elimination in Ukraine, standard international approaches to clinical, laboratory and epidemiological diagnosis of cases, investigation of viruses transmission chains and detection of endemicity cases are in the course of implementation. Quality of the executing activities is assessed according to relevant standard indicators.Библиографические ссылки
Timchenko VN, Kaplina TA, Bulina OV, Leonicheva OA, Khakizimana ZhK, Timofeeva EV. [Actual problems of measles]. Pediatr. 2017;8(3):120-9. Russian. doi: 10.17816/PED83120-129
Chudna LM, Zadorozhna VI, Marychev IL, Demchishina IV. [Vaccine and its impact on the incidence of infections managed by means of specific immunization]. Profilaktychna medicina. 2013;1-2(20):3-10. Ukrainian.
Zherebtsova NY, Evdokimov VI, Shchibrik EV, Chebotareva TY, Mezenceva AL. [Characteristics of epidemiology of measles in the modern stage in Belgorod region]. Nauchnye vedomosti BelGU. Seriya Meditsina. Farmatsiya. 2014;4(175):253-7. Russian.
MarichevIL, Brizhata SI, Protsap EI, Nekrasova LS, Svita VN,Vasheka LN.[State of measles vaccination inukraineand its impact on the epidemic process]. Profilaktychna medicina. 2012;3-4(19):3-7. Ukrainian.
Krasyuk LS, Bіlomerya TA, AlayevaOM, Kislyak ІІ, Alekseeva ІV, Myshko OV. [Trends of rubella’s epidemic process inukraine]. Profilaktychna medicina. 2012;2(18):57-59. Ukrainian.
MuldersMN, Serhan F, Goodson JL, Icenogle J, Johnson BW,RotaPA. Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms. The Journal of Infectious Diseases. 2017;216(S1):324-330. doi: 10.1093/infdis/jix077
Furuse Y, Oshitani H. Global Transmission Dynamics of Measles in the Measles Elimination Era. Viruses. 2017;9(4):82. doi: 10.3390/v9040082
Orenstein WA, Cairns L, Hinman A, Nkowane B, Olivé JM, Reingold AL. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: background and summary. Vaccine. 2018;36(l):A35-A42. doi: 10.1016/j.vaccine.2017.10.065
O'Connor P, Jankovic D, Muscat M, Ben-Mamou M, Reef S, Papania M, Singh S, Kaloumenos T, Butler R, Datta S. Measles and rubella elimination in the WHO Region forEurope: progress and challenges. Clin Microbiol Infect. 2017;23(8):504-10. doi: 10.1016/j.cmi.2017.01.003
Goodson JL, Alexander JP, Linkins RW, Orenstein WA. Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach. Expert Rev Vaccines. 2017;16(12):1203-16. doi: 10.1080/14760584.2017.1393337
Santibanez S, Hübschen JM, Ben Mamou MC, Muscat M, Brown KE, Myers R, Donoso Mantke O, Zeichhardt H, Brockmann D, Shulga SV, Muller CP, O'Connor PM, Mulders MN, Mankertz A. Molecular surveillance of measles and rubella in the WHO European Region: new challenges in the elimination phase. Clin Microbiol Infect. 2017;23(8):516-23. doi: 10.1016/j.cmi.2017.06.030
Coughlin MM, BeckAS, Bankamp B, RotaPA. Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies. Viruses. 2017;9(1):11. doi: 10.3390/v9010011
Plotkin SA, Reef SE. Rubella Vaccine. In: Plotkin SA,OrensteinWA, Offit PA, editors. Vaccines, fifth edition.Philadelphia(PA), Saunders-Elsevier, 2008;735-1.
Reef SE, Strebel P, Dabbagh A, Gacic-Dobo M, Cochi S. Progress toward control of rubella and prevention of congenital rubella syndrome–worldwide, 2009. J Infect Dis. 2011;204(1);24–7. doi: 10.1093/infdis/jir155
Sniadack DH, Crowcroft NS, Durrheim DN, Rota PA. Roadmap to elimination- standard measles and rubella surveillance. Weekly epidemiological record. 2017;9/10(92):97-105.
Загрузки
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2018 Medicni perspektivi
![Лицензия Creative Commons](http://i.creativecommons.org/l/by/4.0/88x31.png)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.